Cargando…

Inhibition of protein kinase C delta leads to cellular senescence to induce anti‐tumor effects in colorectal cancer

Protein kinase C delta (PKCδ) is a multifunctional serine–threonine kinase implicated in cell proliferation, differentiation, tumorigenesis, and therapeutic resistance. However, the molecular mechanism of PKCδ in colorectal cancer (CRC) remains unclear. In this study, we showed that PKCδ acts as a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimoyama, Yuya, Yamada, Kohji, Yoshida, Saishu, Kawamura, Akira, Hannya, Yoshito, Imaizumi, Yuta, Kumamoto, Tomotaka, Takeda, Yasuhiro, Shimoda, Masayuki, Eto, Ken, Yoshida, Kiyotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236638/
https://www.ncbi.nlm.nih.gov/pubmed/36851883
http://dx.doi.org/10.1111/cas.15768
Descripción
Sumario:Protein kinase C delta (PKCδ) is a multifunctional serine–threonine kinase implicated in cell proliferation, differentiation, tumorigenesis, and therapeutic resistance. However, the molecular mechanism of PKCδ in colorectal cancer (CRC) remains unclear. In this study, we showed that PKCδ acts as a negative regulator of cellular senescence in p53 wild‐type (wt‐p53) CRC. Immunohistochemical analysis revealed that PKCδ levels in human CRC tissues were higher than those in the surrounding normal tissues. Deletion studies have shown that cell proliferation and tumorigenesis in wt‐p53 CRC is sensitive to PKCδ expression. We found that PKCδ activates p21 via a p53‐independent pathway and that PKCδ‐kinase activity is essential for p21 activity. In addition, both repression of PKCδ expression and inhibition of PKCδ activity induced cellular senescence‐like phenotypes, including increased senescence‐associated β‐galactosidase (SA‐β‐gal) staining, low LaminB1 expression, large nucleus size, and senescence‐associated secretory phenotype (SASP) detection. Finally, a kinase inhibitor of PKCδ suppressed senescence‐dependent tumorigenicity in a dose‐dependent manner. These results offer a mechanistic insight into CRC survival and tumorigenesis. In addition, a novel therapeutic strategy for wt‐p53 CRC is proposed.